Jiangsu Nhwa Pharmaceutical Corporation Ltd. is an integrated pharmaceutical corporation conducting technology, industry and distribution, and is the designated manufacturer of psychotropic drugs by National Ministry of Health. The company has been entitled as the National Hi-tech Enterprise and ranked among National Top 100 Pharmaceutical Enterprises, with Post-Doctoral Research Center, Post-Doctoral Innovation Center and Nationally Designated Technology Center, It's a public corporation listed on Shenzhen SME board, and the brandcertified corporation of International Environmental Standard System (ISO14000). Nhwa has been appraised as the famous brand in China. The corporation mainly deals in manufacturing the Central Nervous System (CNS) medicines, owning two large-scale pharmaceutical production facilities of APIs and Drugs, which cover a total of over 400 mu (1 mu equivalents to 667 sq.m.). The major products include tens of dosage forms of tablets, capsules, small dose injections, freeze-dried powders, and Chinese medicines. Currently, there are 27 kinds of APIs with annual yield of 350 tons and 90 kinds of dosage forms with annual production capacity of 2 billion tablets, 300 million capsules and 100 million injections.
Product Categories
Jiangsu Nhwa Pharmaceutical Corporation Ltd. is an integrated pharmaceutical corporation conducting technology, industry and distribution, and is the designated manufacturer of psychotropic drugs by National Ministry of Health. The company has been entitled as the National Hi-tech Enterprise and ranked among National Top 100 Pharmaceutical Enterprises, with Post-Doctoral Research Center, Post-Doctoral Innovation Center and Nationally Designated Technology Center, It's a public corporation listed on Shenzhen SME board, and the brandcertified corporation of International Environmental Standard System (ISO14000). Nhwa has been appraised as the famous brand in China. The corporation mainly deals in manufacturing the Central Nervous System (CNS) medicines, owning two large-scale pharmaceutical production facilities of APIs and Drugs, which cover a total of over 400 mu (1 mu equivalents to 667 sq.m.). The major products include tens of dosage forms of tablets, capsules, small dose injections, freeze-dried powders, and Chinese medicines. Currently, there are 27 kinds of APIs with annual yield of 350 tons and 90 kinds of dosage forms with annual production capacity of 2 billion tablets, 300 million capsules and 100 million injections.